Latest treatment news and information for patient advocates and people working in hepatitis in Europe. Find out more about infohep > NAM working with the World Hepatitis Alliance and the European Liver Patients Association www.nam.org.uk www.worldhepatitisalliance.org www.elpa-info.org Image: PexelsNews from infohep.org, December 2020Read our December hepatitis news bulletin. News from The Liver Meeting 2020Visit our AASLD Liver Meeting conference pages. Image: Tanya Nova/PixabayPrisonersHigh hepatitis C cure rate achieved in New York prisons. Image: Gerd Altmann/PixabayThe Liver Meeting 2020: COVID-19Which people with chronic liver disease have higher COVID-19 risks? Hepatitis bulletinSign up for our monthly hepatitis bulletin. New to hepatitis?Read our introductory information on viral hepatitis > infohep news Coronavirus Will people with liver disease be prioritised for COVID-19 vaccination? Keith Alcorn / 19 January 2021 People with decompensated cirrhosis should be prioritised for COVID-19 vaccination and immunosuppressive treatment after a liver transplant should not be a barrier to vaccination, an international panel of liver experts has concluded. Their review ... Hepatitis C elimination What's needed to eliminate hepatitis C in people with HIV in Scotland? Keith Alcorn / 18 January 2021 To eliminate hepatitis C in people with HIV in Scotland, healthcare providers will need to reach people not on HIV treatment and step up testing for hepatitis C in people ... Access to medicines & diagnostics Public-sector hepatitis C treatment programmes expanding in lower- and middle-income countries Keith Alcorn / 08 January 2021 Public-sector hepatitis C treatment programmes have cured tens of thousands of people in lower- and lower-middle-income countries with the aid of low-cost direct-acting antivirals and diagnostics, a simplified approach to treatment and large-scale ... Experimental treatments for NASH/NAFLD Semaglutide alone or in combination regimens shows promise for NASH Liz Highleyman / 18 December 2020 Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ... Experimental treatments for NASH/NAFLD Lanifibranor improves NASH in 24-week trial Keith Alcorn / 18 December 2020 Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ... View all infohep news Editors' picks from other sources On Waitlist for Liver Transplants, Women Die More Often Than Men Healthday / 18 January 2021 Liver Stiffness Before Hepatitis C Treatment Predicts Liver Cancer Risk Hep Mag / 18 January 2021 Launch of new international liver patients organization Liver Patients International / 18 January 2021 Major hep B players Gilead and Vir join forces to find a cure Fierce Biotech / 18 January 2021 London comes together to treat hepatitis C during lockdown London Joint Working Group on Substance Use and Hepatitis C / 18 December 2020 WHO-commissioned global systematic review finds high HCV prevalence and incidence among men who have sex with men World Health Organization / 18 November 2020 State Policies Create Barriers to Hepatitis C Elimination Hep Mag / 17 November 2020 New tool to predict outcomes in cirrhosis of the liver Baylor College of Medicine / 11 November 2020 Increased Coffee Intake May Lower Risk of Liver-Related Death HepMag / 27 October 2020 Hepatitis C eradication in Korea 10 years behind WHO target Korea Biomedical News / 13 October 2020 View all news from other sources Latest library resources Safer heroin injecting TypeWeb page Published2013 AuthorJon Derricott A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel [2012] TypeWeb page CountryRussian Federation, Turkey, Western and Central Europe Published2013 AuthorLiver International Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012 TypeWeb page CountryUnited States PublishedApril 2013 AuthorAmerican Association for the Study of Liver Diseases View all resources Looking for country specific news, resources and services?Visit our country information pages > Keep up to date with the latest hepatitis newsSign up for our free monthly email bulletin >